INDICATORS FOR THE EVALUATION OF THE PROGRAMME
ANNEX IISupplementary provisions
ANNEX II INDICATORS FOR THE EVALUATION OF THE PROGRAMME Programme indicators: 1. Preparedness and response planning of the Union and of Member States for serious cross-border threats to health 2. Access to centrally authorised medicinal products, for example the number of existing and new orphan authorisations, advanced therapy medicinal products (ATMPs), medicinal products for paediatric use or vaccines, for unmet needs 3. Number of actions contributing to the reduction of avoidable mortality in the area of non-communicable diseases and risk factors 4. Number of Member States implementing best practices regarding health promotion, disease prevention and addressing health inequalities 5. Number of Member States participating in the European health data space 6. Number of Member States with improved preparedness and response planning 7. Vaccination coverage by age for vaccine-preventable-diseases such as measles, flu, HPV and COVID-19 8. EU Laboratory capacity index (EULabCap) 9. Age-standardised five-year net survival rate for paediatric cancer by type, age, gender and Member State (to the extent available) 10. Screening coverage for breast, cervical and colorectal cancer screening programmes, by type, target population, and Member State 11. Percentage of population covered by Cancer Registries and number of Member States reporting information on cervical, breast, colorectal and paediatric cancer stage at diagnosis 12. Number of actions addressing the prevalence of major chronic diseases per Member State, by disease, gender and age 13. Number of actions addressing the age prevalence of tobacco use, if possible differentiated by gender 14. Number of actions addressing the prevalence of harmful use of alcohol, if possible differentiated by gender and age 15. Number of shortages of medicinal products in the Member States as reported through the single point of contact network 16. Number of actions aimed at increasing the security and continuity of the global supply chains and addressing dependence on imports from third countries for the production of essential active pharmaceutical ingredients and medicinal products in the Union 17. Number of audits conducted in the Union and in third countries to ensure good manufacturing practices and good clinical practices (Union control) 18. Antimicrobial consumption for systemic use ATC (group J01) per Member State 19. Number of healthcare units involved in ERNs and of patients diagnosed and treated by the members of ERNs 20. Number of HTA reports jointly carried out 21. Number of health impact assessments of Union policies 22. Number of actions addressing the fight against communicable diseases 23. Number of actions addressing environmental risk factors for health